<DOC>
	<DOCNO>NCT02554799</DOCNO>
	<brief_summary>This study conduct single centre , open single dose two parallel cohort design oral dos MMV390048 administer healthy male female subject 18 55 year age . Subjects screen within 28 day prior enter study . On Day 1 study subject receive one two MMV390048 prototype formulation , dose 40 mg 240 mL water . Subjects discharge Day 3 48h post-dose attend unit follow-up visit Days 5 , 7 , 10 , 14 , 19 , 26 29 .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Oral Formulations MMV390048 Administered Fasted Healthy Volunteers</brief_title>
	<detailed_description>A Phase 1 exploratory study evaluate pharmacokinetics select oral formulation MMV390048 administer healthy volunteer . It anticipate eighteen ( 18 ) healthy male female subject include study , however option include additional cohort 9 subject . The optional cohort would receive single dose formulation consider least pharmacokinetic variability suitable safety tolerability profile food milk . Timing PK sample may adjust accordance evolve data dose schedule . Additional few PK sample may take accordance evolve data dose schedule establish full protocol specific PK profile . The study specific maximum blood volume take exceed .</detailed_description>
	<criteria>healthy male female ( nonchildbearing potential ) race , age 18 55 year body weight least 50kg body mass index 18 30Kg/m2 Females must nonchildbearing potential : Natural ( spontaneous ) postmenopausal define ( amenorrheic least 12 month without alternative medical cause screen follicle stimulate hormone level &gt; 25IU/L ( postmenopause ) . Premenopausal irreversible surgical sterilization hysterectomy and/or bilateral oophorectomy salpingectomy least 6 month screen Males agree use acceptable method contraception male subject 's partner could become pregnant time study medication 120 day administration study medication . One follow acceptable method contraception must use : Condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Surgical sterilization ( vasectomy documentation azoospermia ) acceptable barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] use spermicidal foam/gel/film/cream/suppository ) subject 's female partner use oral contraceptive ( combination estrogen / progesterone pill ) , injectable progesterone subdermal implant acceptable barrier method subject 's female partner use medically prescribe topically apply transdermal contraceptive patch acceptable barrier method subject 's female partner undergone document tubal ligation ( female sterilization ) . In addition , acceptable barrier method must use . subject 's female partner undergone document placement intrauterine device intrauterine system . In addition , acceptable barrier method must use . True abstinence : line prefer usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Abstinent subject agree use 1 abovementioned contraceptive method , start sexual relationship study 120 day poststudy drug nonsmoker exsmokers 90 day prior screen smoke 5 cigarette per day . If user nicotine product ( spray , patch , ecigarette , etc . ) use equivalent 5 cigarette /day Subjects donate egg sperm time administration study medication 120 day poststudy drug capable fully understand comply requirement study must sign informed consent form prior undergoing studyrelated procedure agree avoid excessive UV radiation exposure ( occupational exposure sun , sunbathing , tan salon use , phototherapy , etc . ) throughout study . Male subject female partner ( ) ( ) pregnant lactate time study medication Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean Current recurrent disease ( e.g . cardiovascular , neurological , renal , gastrointestinal , oncologic condition ) may affect action , absorption disposition study medication could affect clinical assessment clinical laboratory evaluation Current relevant history physical psychiatric illness may require treatment make subject unlikely fully comply requirement complete study , condition present undue risk investigational product study procedures Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study History photosensitivity History clinical evidence alcohol substance abuse . Alcohol abuse define regular weekly intake 21 unit male 14 unit females Any clinically relevant history intolerance/allergy milk dairy product Use investigational product participation clinical study within 90 day study medication Donation blood product 500ml blood 90 day prior study medication Use prescription drug within 14 day within 5 time elimination halflife ( whichever period longer ) prior study medication Use moderate strong inhibitor and/or inducer CYP450/Transporters within 4 week prior study drug administration ( 5 halflives compound longer ) Use overthecounter medication dietary supplement , include vitamin herbal supplement within 7 day study drug . With exception paracetamol may use incidentally shortterm treatment maximum 2g/day Intake grapefruit , grapefruit juice product contain grapefruit within 28 day prior study drug Excessive intake caffeine drink energy drink within 48 hour admission ( three 250ml cup coffee day , equivalent roughly 250mg caffeine ) Any clinically significant abnormal laboratory , vital sign safety finding determine medical history , physical examination evaluation screen admission . Any liver function test elevate &gt; 1.5 time upper limit normal , consider investigator clinically relevant , screen admission Abnormal serum Hemoglobin , Haptoglobin , Reticulocyte count Lactate Dehydrogenase screening/admission abnormal ECG result screening/admission result consider clinically significant investigator Confirmed positive urine drug screen ( amphetamine , benzodiazepine , cocaine , cannabinoids , opiate , barbiturates methadone ) alcohol breath test screening/admission . positive human immunodeficiency virus , hepatitis B surface antigen , anti Hepatitis core antibody , hepatitis C virus antibody screen vein unsuitable intravenous puncture cannulation either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) 23 . Any condition opinion investigator would make subject unsuitable enrolment could interfere subject ' participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>